Filter By Category
Archives
Share on -
CUSTIRSEN
Generic Name: CUSTIRSEN
ABSTRACT -
Custirsen is an investigational antisense oligonucleotide designed to reduce clusterin expression. Clusterin is associated with cell-survival signaling and treatment resistance; downregulation was investigated as a chemosensitizing strategy in prostate cancer and other malignancies.
DOSAGE -
No approved standard dose is established. Oncology studies evaluated intravenous custirsen sodium, including a 640 mg weekly regimen combined with docetaxel and prednisone in metastatic castration-resistant prostate cancer trials.
SIDE EEFECTS -
- Fever, chills, rigors, fatigue, or flu-like symptoms
- Nausea, vomiting, anorexia, or mucositis
- Anemia, thrombocytopenia, leukopenia, or neutropenia
- Dyspnea, pleural effusion, or fluid-related symptoms in susceptible patients
- Injection/infusion-related reactions and laboratory abnormalities
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash, itching, hives, or flushing
- Swelling of the face, lips, tongue, or throat
- Breathing difficulty, wheezing, or chest tightness
- Severe dizziness, hypotension, or anaphylaxis
DRUG INTERACTIONS-
- Combination with cytotoxic chemotherapy may increase myelosuppression and infection risk
- Anticoagulants or antiplatelet drugs may require closer monitoring if platelet counts fall
- Nephrotoxic or fluid-retaining medicines may complicate tolerability
- Drug interactions are incompletely defined because custirsen remains investigational
PREAUTONS–
- Use only under oncology specialist supervision or a clinical trial protocol
- Monitor blood counts, renal/hepatic function, fluid status, and respiratory symptoms
- Assess infection risk and manage fever or neutropenia promptly
- Pregnancy and lactation safety are not established
- Confirm oligonucleotide identity by sequence/backbone chemistry rather than by a conventional small-molecule drawing
WARNINGS –
- Investigational agent with no routine approved therapeutic use in many jurisdictions
- Serious cytopenias, infections, dyspnea, or effusions may occur with combination therapy
- Not interchangeable with cysteine/cystine nutritional products or other antisense oligonucleotides
- Clinical trials did not establish a survival benefit in some late-stage prostate cancer settings
Share on -
. Developed by